A single ‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma

ConclusionThis study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data.

Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng, Shiyuan Zhang, Min Xiao, Jia Gu, Liang Huang, Xiaoxi Zhou Tags: RESEARCH ARTICLE Source Type: research